Clinical Trials Logo

Anemia clinical trials

View clinical trials related to Anemia.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT03948867 Enrolling by invitation - Clinical trials for Sickle Cell Anemia in Children

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

Start date: April 24, 2019
Phase: Phase 2
Study type: Interventional

This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population; and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary stroke risk.

NCT ID: NCT03897673 Enrolling by invitation - Anemia Clinical Trials

Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas

OptiM
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Daily iron (ferrous sulfate, 2 mg/kg/day) or placebo syrup for first four months (112 days) of the 12-month (336-day) study. Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month. Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.

NCT ID: NCT03895164 Enrolling by invitation - Anemia Clinical Trials

Linear Programming Approach to Develop Local Specific Food-based Complementary Feeding Recommendation

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

Stunting and anemia amongst under-two children are attributable to poor nutrient intakes. The study evaluates the effectiveness of nutrition education on local specific food-based complementary feeding recommendation (CFR) to improve dietary patterns and nutritional intakes, as well as reduce stunting and anemia among under-two children.

NCT ID: NCT03246178 Enrolling by invitation - Clinical trials for Severe Aplastic Anemia

Haploidentical Transplantation in Severe Aplastic Anemia

Start date: July 10, 2017
Phase: N/A
Study type: Interventional

This is a prospective case-control study on SAA patients treated with HSCT, order to further discuss and assess the safety, feasibility and effectiveness of HFD-HSCT which performed with reduced-intensity fludarabine-based conditioning regimen.Our findings would indicate that SAA patients who lack MSD benefited most if HFD-HSCT was performed with reduced-intensity fludarabine-based conditioning regimen, and our improved outcomes with HFD-HSCT may lead to a salvaged therapy and an expanded direct role for SAA in the future.

NCT ID: NCT03229954 Enrolling by invitation - Clinical trials for Post Gastrectomy Anemia

Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial

Start date: August 28, 2017
Phase: Phase 4
Study type: Interventional

Iron deficiency anemia is a common complication in patients who underwent gastrectomy and leads to a deterioration in patient's quality of life. Therefore iron supplementation is one of the important treatments in postgastrectomy patients. Taking an oral iron is an option for iron supplementation, but the postgastrectomy patients has poor absorption of iron due to their anatomic change. Accordingly, intravenous iron supplementation has been emerged as another treatment option, but there are only a few studies to evaluate the efficacy of intravenous iron supplementation compared with oral iron in patients underwent gastrectomy. Therefore, this study aims to evaluate the iron supplementation method as intravenous injection of iron isomaltoside compared with oral iron in the treatment of postgastrectomy anemia. Gastric cancer patients who underwent curative gastrectomy more than 1 year ago and hemoglobin level lower than 11 g/dL will be included in this trial. After the registration, the patients will be randomly assigned to intravenous iron (n = 179) or oral iron groups (n = 179). Calculated dose of iron isomaltoside using Ganzoni formula will be injected intravenously in intravenous iron group and 160 mg/day of ferrous sulfate for 12 weeks will be taken in oral iron group. Hemoglobin and iron profiles at baseline and weeks 2, 4, 8, and 12 and quality of life score at baseline and weeks 12 period will be evaluated.

NCT ID: NCT02247973 Enrolling by invitation - Clinical trials for Severe Aplastic Anemia

Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The study is a phase II trial designed to evaluate the efficacy and safety of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.

NCT ID: NCT01881503 Enrolling by invitation - Anemia Clinical Trials

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of this expanded access study is to be able to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. HBOC-201 is not FDA approved for use in the United States, but is approved as an oxygen carrier in South Africa and Russia.

NCT ID: NCT01632761 Enrolling by invitation - Anemia Clinical Trials

Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia

Start date: November 2012
Phase: N/A
Study type: Interventional

The VITamin D and OmegaA-3 TriaL (VITAL; NCT01169259) is a randomized clinical trial in 20,000 U.S. men and women studying whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among VITAL participants and will study whether vitamin D or fish oil: (A) in the overall VITAL cohort, reduces the number of persons diagnosed with anemia and (B) in a subcohort of 900 participants seen in Boston, effects long-term changes of the proteins in blood in both anemic and non-anemic individuals who provide blood samples at the start of the study and again 2 years later.

NCT ID: NCT01017627 Enrolling by invitation - Anemia Clinical Trials

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

Start date: November 2009
Phase: N/A
Study type: Interventional

The investigators hypothesize that the post-hospitalized patient status is characterized by subacute and reversible metabolic and hematological changes that, if addressed and treated in a timely manner, would result in a reduced risk for repeat hospitalization. Consequently, a structured quality improvement program, focused on increasing adherence to company wide anemia management policies (ie hemoglobin monitoring within the first 3-5 days post-hospitalization, followed by an appropriate EPO dose modification within the 7 days post-hospitalization), will significantly decrease the risk of hospital re-admission in the 30 days after discharge.